Patents by Inventor Gabriel CASTILLE

Gabriel CASTILLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enveloped Virus Resistant to Complement Inactivation for the Treatment of Cancer
    Publication number: 20220169701
    Abstract: A recombinant fusion protein is disclosed. The fusion protein comprises: (a) a CD55 peptide sequence, (b) a linker sequence C-terminal to the CD55 sequence, (c) a transmembrane domain C-terminal to the linker sequence, and (d) an intracellular domain C-terminal to the transmembrane domain. The fusion protein does not contain a GPI anchor. The fusion protein can be expressed with an N-terminal secretory signal peptide, which is cleaved to yield the mature protein on the surface of a cell line or an enveloped virus. An oncolytic virus expressing the fusion protein is resistant to complement inactivation and can be used to treat cancer.
    Type: Application
    Filed: February 18, 2022
    Publication date: June 2, 2022
    Inventors: Tianci LUO, Rene MOLINA, Gabriel CASTILLE
  • Enveloped virus resistant to complement inactivation for the treatment of cancer
    Patent number: 11274141
    Abstract: A recombinant fusion protein is disclosed. The fusion protein comprises: (a) a CD55 peptide sequence, (b) a linker sequence C-terminal to the CD55 sequence, (c) a transmembrane domain C-terminal to the linker sequence, and (d) an intracellular domain C-terminal to the transmembrane domain. The fusion protein does not contain a GPI anchor. The fusion protein can be expressed with an N-terminal secretory signal peptide, which is cleaved to yield the mature protein on the surface of a cell line or an enveloped virus. An oncolytic virus expressing the fusion protein is resistant to complement inactivation and can be used to treat cancer.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: March 15, 2022
    Assignee: Wellstat ImmunoTherapeutics, LLC
    Inventors: Tianci Luo, Rene Molina, Gabriel Castille
  • Enveloped Virus Resistant to Complement Inactivation for the Treatment of Cancer
    Publication number: 20190194292
    Abstract: A recombinant fusion protein is disclosed. The fusion protein comprises: (a) a CD55 peptide sequence, (b) a linker sequence C-terminal to the CD55 sequence, (c) a transmembrane domain C-terminal to the linker sequence, and (d) an intracellular domain C-terminal to the transmembrane domain. The fusion protein does not contain a GPI anchor. The fusion protein can be expressed with an N-terminal secretory signal peptide, which is cleaved to yield the mature protein on the surface of a cell line or an enveloped virus. An oncolytic virus expressing the fusion protein is resistant to complement inactivation and can be used to treat cancer.
    Type: Application
    Filed: May 10, 2018
    Publication date: June 27, 2019
    Inventors: Tianci LUO, Rene MOLINA, Gabriel CASTILLE